SCHEDULE: Armistice Capital Discloses Ekso Bionics Stake

Armistice Capital, LLC and Steven Boyd have reported a 4.99% stake in Ekso Bionics Holdings, Inc. as of March 31, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, indicating beneficial ownership of 187,151 shares of Ekso Bionics Holdings, Inc. common stock.
• This ownership represents 4.99% of the class of securities.
• The filing is an amendment (Amendment No. 4) and the event date requiring the filing is March 31, 2026.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports ownership without providing operational or financial performance details of the underlying company.

Positives

• Armistice Capital, LLC and Steven Boyd have disclosed a significant ownership stake, which could indicate confidence in Ekso Bionics Holdings, Inc.'s future prospects.
• The ownership level of 4.99% is just below the threshold that would trigger more stringent reporting requirements, suggesting a strategic approach to their investment.

Negatives

• The filing does not contain any specific financial performance data or operational updates for Ekso Bionics Holdings, Inc., making it difficult to assess the underlying business health.
• The Master Fund, the direct holder of the shares, disclaims beneficial ownership due to the investment management agreement, which adds a layer of complexity to the ownership structure.

Risks

• The filing does not explicitly mention any risks associated with Ekso Bionics Holdings, Inc. or the investment itself.
• Potential future changes in ownership or investment strategy by Armistice Capital could impact Ekso Bionics Holdings, Inc.'s stock.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Ekso Bionics Holdings, Inc. or the reporting persons.

Management Comments

• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
• Steven Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes. The reporting persons are investment managers, suggesting a strategic allocation within their portfolio, rather than an activist approach at this ownership level.

Stakeholder Impact

• Shareholders of Ekso Bionics Holdings, Inc. may view the increased institutional interest as a positive sign, though the passive nature of this filing limits immediate impact.
• The reporting persons, as significant shareholders, will have an interest in the company's performance and governance.

Next Steps

• Armistice Capital, LLC and Steven Boyd will continue to hold their stake in Ekso Bionics Holdings, Inc.
• Future amendments to this Schedule 13G will be filed if there are changes in beneficial ownership.

Key Dates

Keywords

Ekso Bionics Holdings, Schedule 13G, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, SEC Filing, Investment Management